Markov model and cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer
American Journal of Clinical Oncology: Cancer Clinical Trials, Volume 37, No. 5, Year 2013
Notification
URL copied to clipboard!
Purpose: Metastatic breast cancer (MBC) remains an incurable disease despite advances in treatment modalities. In 2008, the FDA approved bevacizumab with paclitaxel for the initial treatment of HER2-negative MBC. The approval was then officially revoked by the FDA in November 2011. However, both the European Medicines Agency and NCCN still endorse bevacizumab for this indication. One of the greatest challenges facing health care worldwide is reconciling incremental clinical benefits with exponentially rising costs. This study aimed to assess the cost-effectiveness of bevacizumab with paclitaxel for HER2-negative MBC.